Advancements In Process And Payload Development For ADCs And Next-Generation Bioconjugates

Continuous advancements in the process and payload development of Antibody-Drug Conjugates (ADCs) and next-generation bioconjugates have the potential to enhance targeted therapeutics and improve patient treatment options.

Learn about adapting conjugation processes and analytics to non-traditional ADCs as well as integrating Process Analytical Technology (PAT) into development and manufacturing. With a focus on linker payloads, explore key strategies for accessing and solubilizing drug linkers. The insights, templates, and technologies covered in this webinar aim to empower ADC developers, equipping them with the necessary tools to introduce novel therapies to patients with confidence.